NAS10027,087+1.72%S&P7,401+0.65%GOLD$4,073−1.00%BTC$75,828−0.15%VIX24.55−12.88%latest tape · as of 20:03 UTC
The Screen · Consumer Cyclical · Internet Retail
REREATRenew Inc.
RERE · the NYSE · USD · Market cap $952M · 2,389 employees
ATRenew Inc., together with its subsidiaries, sell pre-owned consumer electronics through its online platforms and other channels in the People's Republic of China.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price4.30 USD
Fair value8.08
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-29Read Accumulation3.99+7.8% to today ✓Markdown gives way to Accumulation
2026-10-22Read Markdown3.94+9.1% to today Accumulation gives way to Markdown first Markdown read since October
2026-10-15Read Accumulation3.76+14.4% to today ✓Markdown gives way to Accumulation after a 9% slide in 5 weeks
2026-09-11Read Markdown4.14+3.9% to today Accumulation gives way to Markdown after a 7% rise in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
ATRenew Inc. holds its Accumulation at $4.30. The statistical read favours the sellers, held for 143 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 143 days
Price at the screen
$4.30
Valuation
15.36 trailing · 7.51 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.46
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
7.65%
Below 33%
Interest-bearing debt is just 7.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
5.53%
Below 33%
Cash held in interest-bearing accounts and securities is 5.5% of assets, under the one-third limit.
Pass
Receivables
27.98%
Below 49%
Money owed to the company is 28.0% of assets, under the 49% limit.
Pass
Revenue purity
0.10%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
ATRenew clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 8%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RERE's ethical verdict changes
Today RERE passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 47% discount to our $8.08 fair value, 32.40% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 46.8% discount to the base estimate.
Where our models see it going: fair-value estimate $8.08, with a range of $8.08 to $8.60, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it stands out
A 32%-growth business trading at just 7.5x forward earnings, with minimal debt. That is a 47% discount to our $8.08 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 4 analysts rate it Strong Buy with a $6.48 average target, about 51% above the screened price.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to China and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RERE trades on the NYSE (the company is based in China). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Accumulation · changed$3.99+1.3%Entry 9
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it strong buy, with a mean price target of $7.
2026-10-22Markdown · changed$3.94+4.8%Entry 8
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it strong buy, with a mean price target of $7.
2026-10-15Accumulation · changed$3.76-4.6%Entry 7
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it strong buy, with a mean price target of $7.
2026-10-02Markdown$3.94-4.8%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it strong buy, with a mean price target of $7.
2026-09-11Markdown · changed$4.14+7.0%Entry 5
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 7.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it strong buy, with a mean price target of $7.
2026-08-11Accumulation · changed$3.87-1.5%Entry 4
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it strong buy, with a mean price target of $7.
2026-07-18Markup$3.93+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it strong buy, with a mean price target of $7.
2026-07-03Markup$3.93+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$3.93Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.